Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals.

Bomba M, Ciavardelli D, Silvestri E, Canzoniero LM, Lattanzio R, Chiappini P, Piantelli M, Di Ilio C, Consoli A, Sensi SL.

Cell Death Dis. 2013 May 2;4:e612. doi: 10.1038/cddis.2013.139.

2.

Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice.

Dragicevic N, Mamcarz M, Zhu Y, Buzzeo R, Tan J, Arendash GW, Bradshaw PC.

J Alzheimers Dis. 2010;20 Suppl 2:S535-50. doi: 10.3233/JAD-2010-100342.

PMID:
20463404
3.

The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.

McClean PL, Parthsarathy V, Faivre E, Hölscher C.

J Neurosci. 2011 Apr 27;31(17):6587-94. doi: 10.1523/JNEUROSCI.0529-11.2011.

5.

Restoration of dopamine release deficits during object recognition memory acquisition attenuates cognitive impairment in a triple transgenic mice model of Alzheimer's disease.

Guzmán-Ramos K, Moreno-Castilla P, Castro-Cruz M, McGaugh JL, Martínez-Coria H, LaFerla FM, Bermúdez-Rattoni F.

Learn Mem. 2012 Sep 14;19(10):453-60. doi: 10.1101/lm.026070.112.

PMID:
22984283
6.

Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Aβ and tau pathologies in 3xTg-AD mice.

Blanchard J, Wanka L, Tung YC, Cárdenas-Aguayo Mdel C, LaFerla FM, Iqbal K, Grundke-Iqbal I.

Acta Neuropathol. 2010 Nov;120(5):605-21. doi: 10.1007/s00401-010-0734-6. Epub 2010 Aug 10.

PMID:
20697724
7.

Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats.

Solmaz V, Çınar BP, Yiğittürk G, Çavuşoğlu T, Taşkıran D, Erbaş O.

Eur J Pharmacol. 2015 Oct 15;765:482-7. doi: 10.1016/j.ejphar.2015.09.024. Epub 2015 Sep 16.

PMID:
26386291
8.

Effects of dietary supplementation of carnosine on mitochondrial dysfunction, amyloid pathology, and cognitive deficits in 3xTg-AD mice.

Corona C, Frazzini V, Silvestri E, Lattanzio R, La Sorda R, Piantelli M, Canzoniero LM, Ciavardelli D, Rizzarelli E, Sensi SL.

PLoS One. 2011 Mar 15;6(3):e17971. doi: 10.1371/journal.pone.0017971.

9.

Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice.

Masciopinto F, Di Pietro N, Corona C, Bomba M, Pipino C, Curcio M, Di Castelnuovo A, Ciavardelli D, Silvestri E, Canzoniero LM, Sekler I, Pandolfi A, Sensi SL.

Cell Death Dis. 2012 Dec 20;3:e448. doi: 10.1038/cddis.2012.189.

10.

Dietary zinc supplementation of 3xTg-AD mice increases BDNF levels and prevents cognitive deficits as well as mitochondrial dysfunction.

Corona C, Masciopinto F, Silvestri E, Viscovo AD, Lattanzio R, Sorda RL, Ciavardelli D, Goglia F, Piantelli M, Canzoniero LM, Sensi SL.

Cell Death Dis. 2010 Oct 28;1:e91. doi: 10.1038/cddis.2010.73.

11.

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.

Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG.

J Clin Invest. 2012 Apr;122(4):1339-53. doi: 10.1172/JCI57256.

12.

Physical exercise protects against Alzheimer's disease in 3xTg-AD mice.

García-Mesa Y, López-Ramos JC, Giménez-Llort L, Revilla S, Guerra R, Gruart A, Laferla FM, Cristòfol R, Delgado-García JM, Sanfeliu C.

J Alzheimers Dis. 2011;24(3):421-54. doi: 10.3233/JAD-2011-101635.

PMID:
21297257
13.

GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.

Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, Tweedie D, Perry T, Mattson MP, Kapogiannis D, Sambamurti K, Lahiri DK, Greig NH.

J Alzheimers Dis. 2010;19(4):1205-19. doi: 10.3233/JAD-2010-1314.

14.

Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.

Schnabel CA, Wintle M, Kolterman O.

Vasc Health Risk Manag. 2006;2(1):69-77. Review.

15.

α7 Nicotinic receptor agonist enhances cognition in aged 3xTg-AD mice with robust plaques and tangles.

Medeiros R, Castello NA, Cheng D, Kitazawa M, Baglietto-Vargas D, Green KN, Esbenshade TA, Bitner RS, Decker MW, LaFerla FM.

Am J Pathol. 2014 Feb;184(2):520-9. doi: 10.1016/j.ajpath.2013.10.010. Epub 2013 Nov 19.

PMID:
24269557
16.

Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus.

Tzefos M, Olin JL.

Ann Pharmacother. 2010 Jul-Aug;44(7-8):1294-300. doi: 10.1345/aph.1P047. Epub 2010 Jun 8. Review.

PMID:
20530705
17.

TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-β deposition in APP/PS1 mice.

Nunes AF, Amaral JD, Lo AC, Fonseca MB, Viana RJ, Callaerts-Vegh Z, D'Hooge R, Rodrigues CM.

Mol Neurobiol. 2012 Jun;45(3):440-54. doi: 10.1007/s12035-012-8256-y. Epub 2012 Mar 23.

PMID:
22438081
18.

Regional brain metabolism with cytochrome c oxidase histochemistry in a PS1/A246E mouse model of autosomal dominant Alzheimer's disease: correlations with behavior and oxidative stress.

Strazielle C, Jazi R, Verdier Y, Qian S, Lalonde R.

Neurochem Int. 2009 Dec;55(8):806-14. doi: 10.1016/j.neuint.2009.08.005. Epub 2009 Aug 12.

PMID:
19682525
19.

Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice.

Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O.

Ann Neurol. 2004 Jun;55(6):801-14.

PMID:
15174014
20.

Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.

Gallwitz B.

Int J Clin Pract. 2006 Dec;60(12):1654-61. Review.

PMID:
17109672

Supplemental Content

Support Center